#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity
MADRID — Pfizer is moving past its late-stage loss in non-small cell lung cancer, pointing to a post-hoc analysis of earlier-line patients who appear to benefit. Also on Sunday, BioNTech and Bristol Myers Squibb touted ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.